All In Biotech

Drug Trial Radar · NCT03473743

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects With Metastatic or Locally Advanced Urothelial Cancer

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

125

Actual

Start

Apr 5, 2018

Primary completion

Sep 30, 2022

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Mar 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to: (a) characterize the safety and tolerability of and to identify the recommended Phase 2 dose (RP2D) and schedule for erdafitinib in combination with cetrelimab, and for erdafitinib in combination with cetrelimab and platinum (cisplatin and carboplatin) chemotherapy and; (b) to evaluate the safety and clinical activity of erdafitinib alone and in combination with cetrelimab in cisplatin-ineligible participants with metastatic or locally advanced urothelial cancer (UC) with select fibroblast growth factor receptor (FGFR) gene alterations and no prior systemic therapy for metastatic disease.

Conditions

  • Urothelial Carcinoma

Interventions

  • ErdafitinibDrug

    Participants will receive erdafitinib orally.

  • CetrelimabDrug

    Participants will receive cetrelimab by intravenous infusion.

  • CisplatinDrug

    Participants will receive cisplatin by intravenous infusion as a part of platinum chemotherapy.

  • CarboplatinDrug

    Participants will receive carboplatin by intravenous infusion as a part of platinum chemotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of Participants With Dose-Limiting Toxicity (DLTs)Time frame: Up to 8 weeks
  2. Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator AssessmentTime frame: From Day 1 up to 36 months
  3. Phase 2: Number of Participants With Treatment-emergent Adverse Event (TEAEs)Time frame: From Day 1 up to 36 months

Locations

127 sites in 13 countries. Site status is shown where the registry gives one.

  • Rocky Mountain Cancer Centers

    Aurora, Colorado

  • Norton Cancer Institute

    Louisville, Kentucky

  • Maryland Oncology Hematology, PA

    Rockville, Maryland

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Weill Cornell Medical College - NY Presbyterian Hospital

    New York, New York

  • White Plains Hospital Center for Cancer Care

    White Plains, New York

  • Levine Cancer Institute, Carolinas HealthCare System

    Charlotte, North Carolina

  • Toledo Clinic Cancer Centers

    Toledo, Ohio

  • Penn State Hershey Cancer Institute

    Hershey, Pennsylvania

  • Texas Oncology, P.A.

    Fort Worth, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Brest Regional Oncology Dispensary

    Brest, Belarus

  • Grodno University Hospital

    Grodno, Belarus

  • Gomel Regional Clinical Oncology Dispensary

    Homyel, Belarus

  • State Institution N.N. Alexandrov Republican Scientific and

    Lesnoy, Belarus

  • Minsk city Clinical Oncological Dispensary

    Minsk, Belarus

  • Mogilev Regional Hospital

    Mogilev, Belarus

  • Vitebsk Regional Clinical Hospital

    Vitebsk, Belarus

  • ULB Hôpital Erasme

    Brussels, Belgium

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • Jolimont

    Haine-Saint-Paul, Belgium

  • Az Groeninge

    Kortrijk, Belgium

  • CHU de Liège - Domaine Universitaire du Sart Tilman

    Liège, Belgium

  • AZ Nikolaas - Campus Sint-Niklaas Moerland

    Sint-Niklaas, Belgium

  • GZA Ziekenhuizen- Campus St Augustinus

    Wilrijk, Belgium

  • Fundacao Pio XII

    Barretos, Brazil

  • Santa Casa de Misericordia de Belo Horizonte

    Belo Horizonte, Brazil

  • Liga Paranaense de Combate ao Cancer

    Curitiba, Brazil

  • Oncocentro Servicos Medicos e Hospitalares Ltda - Oncocentro

    Fortaleza, Brazil

  • Oncoclinicas Rio de Janeiro S A

    Rio de Janeiro, Brazil

  • Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)

    Rio de Janeiro, Brazil

  • CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia

    Santo André, Brazil

  • Institut de Cancerologie de Ouest (ICO) Site Paul Papin

    Angers, France

  • Hopital Saint André

    Bordeaux, France

  • Centre Francois Baclesse

    Caen, France

  • Centre hospitalier Saint Louis

    La Rochelle, France

  • Centre Leon Berard

    Lyon, France

  • APHM Hopital Timone

    Marseille, France

  • Hopital Europeen Georges Pompidou

    Paris, France

Showing 40 of 127 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.